TRILUMINATE Pivotal - 2-year update EuroPCR 25, presented by G. Singh
The TRILUMINATE Pivotal trial demonstrated that TriClip™ TEER was superior to medical therapy alone at reducing Heart Failure Hospitalization (HFH) risk at 2 years, while confirming its exceptional safety and quality of life improvement
LEARN MORE:
Related Resources
bRIGHT 2-year real-world outcomes
Prognosis of TR after MitraClip for MR
Poster: Primary MR in the Very Elderly
PCR LV 2021: Navitor™ 30-day outcomes
TEER G5 Brochure 2025
EXPAND Study: Data overview
ACC 2023: COAPT™ trial
2-year outcomes from the TRILUMINATE Pivotal trial
The standard of caring for TR
EuroPCR 2022: TAVI 1yr outcomes
TRENDING TOPICS
The standard of caring for TR
TEER G5 Brochure 2025
Poster: Primary MR in the Very Elderly
